Unique ID issued by UMIN | UMIN000053278 |
---|---|
Receipt number | R000060810 |
Scientific Title | Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up) |
Date of disclosure of the study information | 2024/01/09 |
Last modified on | 2024/01/10 18:39:09 |
Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up)
Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up)
Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up)
Retrospective observational study comparing comparing post-COVID conditions incidence in COVID-19 patients between ensitrelvir administration and administration/non-administration of anti-SARS-CoV-2 drugs using large-scale health insurance association data in Japan (3-month follow-up)
Japan |
COVID-19
Infectious disease |
Others
NO
To compare the efficacy of ensitrelvir in reducing post-COVID conditions incidence in COVID-19 patients with molnupiravir, nirmatrelvir or no antiviral as a control using the insurance claims database
Efficacy
Post-COVID conditions incidence from 2 to 3 months after the month of diagnosis of COVID-19
Observational
18 | years-old | <= |
Not applicable |
Male and Female
1. Patients whose index month (IM) of COVID-19 diagnosis is during the enrollment period (2022/11 to 2023/05).
2. Patients with observable period of 6 months before IM
3. Patients with observable period up to 3 months after IM
1. Patients under 18 years of age at the time of IM
2. Patients with dispending days of multiple anti-SARS-CoV-2 drugs in IM
3. Patients with a COVID-19 diagnosis within 3 months prior to IM
4. Patients who have been diagnosed with the same event as the post-COVID condition within 6 months before IM
5. Patients at risk of severe COVID-19
300000
1st name | Yoshitake |
Middle name | |
Last name | Kitanishi |
Shionogi & Co., Ltd.
Data Science Department
541-0047
4F, Midosuji MTR Building, 6-3, Awajimachi 3-chome, Chuo-ku, Osaka-shi, Osaka
06-6202-2161
yoshitake.kitanishi@shionogi.co.jp
1st name | Takuji |
Middle name | |
Last name | Komeda |
Shionogi & Co., Ltd.
Data Science Department
541-0047
4F, Midosuji MTR Building, 6-3, Awajimachi 3-chome, Chuo-ku, Osaka-shi, Osaka
070-7812-6558
takuji.komeda@shionogi.co.jp
Shionogi & Co., Ltd.
Shionogi & Co., Ltd.
Profit organization
Japan
NA
NA
0000000000
XXXX@XXXX
NO
2024 | Year | 01 | Month | 09 | Day |
Unpublished
Preinitiation
2024 | Year | 01 | Month | 05 | Day |
2024 | Year | 01 | Month | 05 | Day |
2025 | Year | 07 | Month | 31 | Day |
None
2024 | Year | 01 | Month | 05 | Day |
2024 | Year | 01 | Month | 10 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000060810
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |